Astrophysics for People in a Hurry, by Neil deGrasse Tyson – Times Higher Education (THE)

Plato had it right when he said that astronomy compels the soul to look upwards. The universe makes for beautiful images and stories littered with superlatives. Astronomers draw on most of modern physics, from gravitation to quantum mechanics, and drive new discoveries in regimes that we could never reach in the laboratory. We develop cutting-edge instrumentation for telescopes on Earth and in space. And our field has a history spanning thousands of years, ever since those first souls looked up and marvelled at the view.

Neil deGrasse Tysons aim is, on the face of it, daunting to convey something of all of this to a level of foundational fluency in only 200 pages. But the presenter of the radio programme StarTalk and the television documentary series Cosmos: A Spacetime Odyssey, one of the most experienced science communicators around, is up to the challenge.

The book is adapted from a series of essays originally written in 1998-2007, and this shows in the format: theres some repetition, and the flow between chapters feels rather random. The upside is that each chapter stands alone, perfect for the busy reader who wants to dip in and out. The breadth of topics is excellent, and includes the Big Bang, dark matter, dark energy, the formation of the elements and the search for life elsewhere in the universe. There is no stinting on physics, and astronomers get some stick for the century-long gap between the discovery of radiation beyond the visible and the development of telescopes in these wavebands. The style is vintage Tyson engaging, chatty and littered with historical and linguistic anecdotes (including a lovely reference to petunias, in a nod to the late, great Douglas Adams).

There are some surprising omissions. There is relatively little on the birth, life and death of stars. The stars dominate our night sky, and Im still amazed by the fact that we understand the processes that differentiate our Sun from the red supergiant Betelgeuse and the white dwarf Sirius B. Supermassive black holes, such as the monster in the centre of our galaxy, get barely a mention, and the chapter on telescopes does not do justice to the full range of new technology at our disposal. However, this is understandable in a slim volume.

Although many scientists are namechecked, I was disappointed that only three women made the cut: Vera Rubin (dark matter pioneer), Jocelyn Bell (discoverer of pulsars) and Carolyn Shoemaker (of comet fame). Stellar physics without Annie Jump Cannon or Cecilia Payne-Gaposchkin, the cosmic distance scale without Henrietta Swan Leavitt, radio astronomy without Ruby Payne-Scott? This is a book that aims to inspire the next generation of scientists, and women have played, and continue to play, a major role in our field.

Tyson opens the book by discussing the allure of astronomy in popular culture. He takes a more sombre view at the end, with a sober assessment of our place in the cosmos and a plea to embrace this cosmic perspective. In an era where it feels that we have to defend science, it is the right way to finish: marvel at the universe, enjoy puzzling it out, and do your utmost to protect our neighbourhood even if youre busy.

Anna Watts is associate professor of astrophysics, University of Amsterdam. She works on neutron stars and the next generation of X-ray space telescopes.

Astrophysics for People in a Hurry By Neil deGrasse Tyson W. W. Norton, 224pp, 14.99 ISBN 9780393609394 Published 2 June 2017

See the rest here:

Astrophysics for People in a Hurry, by Neil deGrasse Tyson - Times Higher Education (THE)

Facebook’s AI training models can now process 40000 images a second – GeekWire

Artificial intelligence researchers at Facebook have figured out how to train their AI models for image recognition at eye-popping speeds.

The company announced the results of the effort to speed up training time at the Data@Scale event in Seattle this morning. Using Facebooks custom GPU (graphics processing unit) hardware and some new algorithms, researchers were able to train their models on 40,000 images a second, making it possible to get through the ImageNet dataset in under an hour with no loss of accuracy, said Pieter Noordhuis, a software engineer at Facebook.

You dont need a proper supercomputer to replicate these results, Noordhuis said.

The system works to associate images with words, which is called supervised learning, he said. Thousands of images from a training set are assigned a description (say, a cat) and the system is shown all of the images with an associated classification. Then, researchers present the system with images of the same object (say, a cat) but without the description attached. If the system knows its looking at a cat, its learning how to associate imagery with descriptive words.

The breakthrough allows Facebook AI researchers to start working on even bigger datasets; like, say, the billions of things posted to its website every day. Its also a display of Facebooks hardware expertise; the company made sure to note that its hardware is open-source, this means that for others to reap these benefits, theres no need for incredibly advanced TPUs, it said in a statement throwing some shade at Googles recent TPU announcement at Google I/O.

Facebook plans to release more details about its AI training work in a research paper published to its Facebook Research page.

Link:

Facebook's AI training models can now process 40000 images a second - GeekWire

Artificial intelligence’s potential impacts raise promising possibilities, societal challenges – Phys.Org

June 8, 2017 by Joe Kullman ASU Professor Subbarao Kambhampati with one of the robots used in his lab teams research aimed at enabling effective collaboration between humans and intelligent robots. The wooden blocks spell out the name of the lab, Yochan, meaning thought or plan in the Sanskrit language. Credit: Marco-Alexis Chaira/ASU

Interest in artificial intelligence has exploded, with some predicting that machines will take over and others optimistically hoping that people will be freed up to explore creative pursuits.

According to Arizona State University Professor Subbarao Kambhampati, the reality will be more in the middlebut the technology will certainly bring about a restructuring of our society.

AI will accomplish a lot of good things, Kambhampati said, but we must also be vigilant about possible ramifications of the technology. And yes, some jobs will be lostbut maybe not the ones people most often think of.

The professor of computer science and engineering in ASU's Ira A. Fulton Schools of Engineering is well qualified to enter the debate. He has been doing work in the areacommonly called "AI"for more than three decades, and he is at the midpoint of a two-year term as president of the international Association for the Advancement of Artificial Intelligence (AAAI), the largest organization of scientists, engineers and others in the field.

Kambhampati, whose current research focuses on developing "human-aware" AI systems to enable people and intelligent machines to work collaboratively, is also on the board of trustees of the Partnership on Artificial Intelligence to Benefit People and Society (PAI), which aims to help establish industry-wide best practices and ethics guidelines.

The following interview is edited from a recent conversation with him.

Question: You became president of the AI association at a time when public awareness of these technologies and the issues they raise has exploded. What's sparking the widespread interest?

Answer: AI as a scientific field has actually been around since the 1950s and has made amazing, if fitful, progress in getting machines to show hallmarks of intelligence. The Deep Blue computer's win over the world chess champion in 1997 was a watershed moment, but even after that, AI remained a staid academic field. Most people didn't come into direct contact with AI technology until relatively recently.

With the recent advances of AI in perceptual intelligence, we all now have smartphones that can hear and talk back to us and recognize images. AI is now a very ubiquitous part of our everyday lives, so there's a visceral understanding of its impact.

Q: Plus, it's a big driver of major industries, right?

A: In 2008, for instance, few if any tech companies were mentioning investments and involvement in AI in their annual reports or quarterly earnings reports. Today you'll find about 300 major companies emphasizing their AI projects or ventures in those reports.

The members of the Partnership for Artificial Intelligence, which I am involved with, include Amazon, Facebook, Google's Deep Mind, IBM and Microsoft. So, yes, AI is now a very big deal.

Q: The big question about AI is what it means for not only business and the economy, but what it portends for society when AI machines are doing more jobs that people used to do. What's your perspective on that?

A: Elon Musk (the prominent engineer, inventor and tech entrepreneur) started this trend of AI fears by remarking that what keeps him up at night is the idea of super-intelligent machines that will become more powerful than humans. Then Stephen Hawking (renowned physicist and cosmologist) chimed in. Statements like that, coming from influential people, of course make the public worry.

I don't take such a pessimistic view. I think AI is going to do a lot of good things. But it is also going to be a very powerful technology that will shape and change our world. So we should remain vigilant of all the ramifications of this powerful technology and work to mitigate unintended consequences. Fortunately, this is a goal shared by both AAAI and PAI.

Q: Garry Kasparov, the former chess champion who was defeated by the Deep Blue computer, writes that we should embrace AI, that it will free people from work so that they can develop their intellectual and creative capabilities. Others are saying the same. Do you agree?

A: I think Kasparov and others who say this are maybe too optimistic. We see from the past that new technology has taken away certain jobs but also created new kinds of jobs. But it's not certain that will always be the case with the proliferation of AI.

It seems clear that some professions are going to disappear, and not just blue-collar jobs like trucking, but also high-paying white-collar jobs. There are going to be many fewer radiologists, because machines are already doing a better job of reading X-rays. Machines can also be much faster and better at doing the kind of information gathering and research now done by paralegals, for instance.

This is why we have to start thinking about how society is going to be restructured if AI technologies and systems are doing much of the work that people once did.

Q: What would such a restructuring look like?

A: This is quite an open question, and organizations like AAAI and PAI are trying to get ahead of the curve in answering it.

I do want to emphasize that I don't think it is solely the job of AI experts, or of industry, to think about these issues of long-term restructuring. This is something that society at large has to contend with. We also have to realize that AI consequences play into already existing social ills such as societal biases, wealth concentration and social alienation. We have to work to make sure that AI moderates rather than amplifies these trends.

Q: What can those in the AI field do proactively to produce the most positive outcomes from the expansion of the technology?

A: We can take potential impacts into consideration when deciding in what directions we want to take our research and development. Much research now, like mine, is focusing on systems that are not intended to replace humans but to augment and enhance what humans are doing. We want to enable humans and machines to work together to do things better than what humans can do alone.

For AI systems to work with humans, they need to acquire emotional and social intelligence, something humans expect from their co-workers. That's where human-aware AI comes into play.

Q: What keeps you excited about your research?

A: I've always thought that the biggest questions facing our age are about three fundamental things: the origin of the universe, the origin of life and the nature of intelligence.

AI research takes you to the heart of one of them. In developing AI systems, I get a window into the basic nature of intelligence. That's why I tell my students that it takes a particularly bad teacher to make AI uninteresting.

That is what hooked me into this work. And now I'm getting the opportunity to go beyond the technical aspects of the field and have a voice on issues of ethics and practices and societal outcomes. That is energizing me even more.

Explore further: AI 'good for the world'... says ultra-lifelike robot

Sophia smiles mischievously, bats her eyelids and tells a joke. Without the mess of cables that make up the back of her head, you could almost mistake her for a human.

Major technology firms have joined forces in a partnership on artificial intelligence, aiming to cooperate on "best practices" on using the technology "to benefit people and society."

Advances in artificial intelligence will soon lead to robots that are capable of nearly everything humans do, threatening tens of millions of jobs in the coming 30 years, experts warned Saturday.

A technology industry alliance devoted to making sure smart machines don't turn against humanity said Friday that Apple has signed on and will have a seat on the board.

The phrase "artificial intelligence" saturates Hollywood dramas from computers taking over spaceships, to sentient robots overpowering humans. Though the real world is perhaps more boring than Hollywood, artificial intelligence ...

Microsoft chief executive Satya Nadella said Wednesday tech developers have a responsibility to prevent a dystopian "1984" future as the US technology titan unveiled a fresh initiative to bring artificial intelligence into ...

An AI machine has taken the maths section of China's annual university entrance exam, finishing it faster than students but with a below average grade.

Globally, from China and Germany to the United States, electric vehicle (EV) subsidies have been championed as an effective strategy to boost production of renewable technology and reduce greenhouse gas emissions (GHG).

As global automakers compete to bring the first flying car to market, Czech pilot Pavel Brezina is trying a different tack: instead of creating a car that flies, he has made a "GyroDrive"a mini helicopter you can drive.

Apple's new HomePod speaker may be music to the ears of its loyal fans, but how much it can crank up volume in the smart speaker market remains to be heard.

Autonomous vehicles with no human backup will be put to the test on publicly traveled roads as early as next year in what may be the first attempt at unassisted autonomous piloting.

Using Earth-abundant materials, EPFL scientists have built the first low-cost system for splitting CO2 into CO, a reaction necessary for turning renewable energy into fuel.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

The rest is here:

Artificial intelligence's potential impacts raise promising possibilities, societal challenges - Phys.Org

Sports Betting: The Next Big Thing for Artificial Intelligence – Investopedia

Quantitative analytical procedures are some of the most successful in the financial world, with an increasing number of money managers turning the grunt work of data processing over to computer algorithms and artificial intelligence (AI). One argument in favor of quantitative methods like these is that they remove the human element from the analytical process, thereby ensuring faster processing times, more thorough analysis, and the effective removal of emotions and potential bias from the process. Now, at least one company is looking to capitalize on the advantages that quantitative methods have over old-fashioned human ones, but in a new area: sports betting.

The new company, Stratagem, is based in London and was set up by an ex-hedge funder, Andreas Koukorinis. In an interview with Business Insider, Koukorinis described his initial efforts at harnessing the powers of quantitative analysis for the purposes of sports betting as "building these robots to let them run around on the floor." He and his team have been developing predictive analytics programs for sports betting procedures, using machine learning and AI to process vast data fields. With these computer systems in place, Koukorinis believes that he will gain an edge in the competitive and often-arbitrary world of sports betting.

Koukorinis has been developing Stratagem for several years, and the company now appears to be taking off. The fund has seen some success with its machine learning models, and Stratagem now has an internal syndicate which allows it to bet its own money and bring in a return. One of the next steps for the fund is to raise around 25 million in the next few months to allow for further growth. Investors will essentially be buying into a sports betting-focused hedge fund.

Charles McGarraugh, CEO of the fledgling company, believes that the model is a straightforward sell to potential investors. "Sports lend themselves well to this kind of predictive analytics because it's a large number of repeated events. And it's uncorrelated to the rest of the market. And the duration of the asset class is short."

Stratagem focuses on both data collection and processing. For the former, the company uses both public sources as well as its own data generation system. Once the data has been gathered, Stratagem uses its analytical tools to crunch the numbers in search of mispriced odds. The results so far have been promising.

Could this be the future of quant methods? Koukorinis and others with Stratagem believe so, seeing a strong connection between the world of sports betting and the hard data analysis that quant is specially designed for. Whether the company will beat the odds remains to be seen.

Read more:

Sports Betting: The Next Big Thing for Artificial Intelligence - Investopedia

Artificial Intelligence gets below average grade in Chinese university entrance exam – Economic Times

BEIJING: An artificial intelligence (AI) machine has taken the maths section of China's annual university entrance exam, finishing it faster than students but with a below average grade.

The artificial intelligence machine -- a tall black box containing 11 servers placed in the centre of a test room -- took two versions of the exam on Wednesday in Chengdu, Sichuan province.

The machine, called AI-MATHS, scored 105 out of 150 in 22 minutes. Students have two hours to complete the test, the official Xinhua news agency reported.

It then spent 10 minutes on another version and scored 100.

Beijing liberal art students who took the maths exam last year scored an average of 109.

Exam questions and the AI machine's answers were both shown on a big screen while three people kept score.

The AI was developed in 2014 by a Chengdu-based company, Zhunxingyunxue Technology, using big data, artificial intelligence and natural language recognition technologies from Tsinghua University.

"I hope next year the machine can improve its performance on logical reasoning and computer algorithms and score over 130," Lin Hui, the company's CEO, was quoted as saying by Xinhua.

"This is not a make-or-break test for a robot. The aim is to train artificial intelligence to learn the way humans reason and deal with numbers," Lin said.

The machine took only one of the four subjects in the crucially important entrance examination, the other three being Chinese, a foreign language and one comprehensive test in either liberal arts or science.

While AI is faster with numbers than humans, it struggles with language.

"For example, the robot had a hard time understanding the words 'students' and 'teachers' on the test and failed to understand the question, so it scored zero for that question," Lin said.

The test was the latest attempt to show how AI technology can perform in comparison to the human brain.

Last year, the Google-owned computer algorithm AlphaGo became the first computer programme to beat an elite player in a full match of the ancient Chinese game of Go.

AlphaGo won again last month, crushing the world's top player, Ke Jie of China, in a three-game sweep.

AlphaGo's feats have fuelled visions of AI that can not only perform pre-programmed tasks, but help humanity look at complex scientific, technical and medical mysteries in new ways.

Visit link:

Artificial Intelligence gets below average grade in Chinese university entrance exam - Economic Times

Artificial intelligence can now predict if someone will die in the next 5 years – Fox News

This AI will tell people when theyre likely to die -- and thats a good thing. Thats because scientists from the University of Adelaide in Australia have used deep learning technology to analyze the computerized tomography (CT) scans of patient organs, in what could one day serve as an early warning system to catch heart disease, cancer, and other diseases early so that intervention can take place.

Using a dataset of historical CT scans, and excluding other predictive factors like age, the system developed by the team was able to predict whether patients would die within five years around 70 percent of the time. The work was described in an article published in the journal Scientific Reports.

The goal of the research isn't really to predict death, but to produce a more accurate measurement of health, Dr. Luke Oakden-Rayner, a researcher on the project, told Digital Trends. A patient's risk of death is directly related to the health of their organs and tissues, but the changes of chronic diseases build up for decades before we get symptoms. By the time we recognize a disease is present it is often quite advanced. So we can take a known outcome, like death, and look back in time at the patient's medical scans to find patterns that relate to undetected disease. Our goal is to identify these changes earlier and more accurately so we can tailor our treatment to individuals.

The AI analyzes CT scans to make its decisions.

At present, this is still a proof-of-concept experiment, however, and Oakden-Rayner points out that theres a lot more work to be done before this becomes the transformative clinical tool it could be. For one thing, the AIs 70-percent predictive accuracy when looking at scans is in line with the manual predictions made by experts. That makes it a potential time-saving tool, or a good means of double-checking, but the hope is that it can be much more than that.

Our next major step is to expand our dataset, Oakden-Rayner continued. We used a very small cohort of 48 patients in this study to show that our approach can work, but in general deep learning works better if you can give it much more data. We are collecting and analyzing a dataset of tens of thousands of cases in the next stage of our project.

The team also aims to expand what the AI is looking for, to help spot things like strokes before they strike.

Link:

Artificial intelligence can now predict if someone will die in the next 5 years - Fox News

The Paris Air Show Will Showcase America’s Aerospace Industrial Might – The National Interest Online (blog)

On June 19th, one of the world largest and most prestigious air shows will open at the Le Bourget airfield outside Paris. This is an event that the aerospace world attends, one which private companies and governments both employ as a stage to showcase some of their best products and impressive capabilities. European companies, in particular, are fond of using the Paris Air Show to launch major new platforms. In addition, it has become quite common for aircraft manufacturers to announce major sales during the show.

Historically, the biennial Paris Air Show has provided a snapshot of the state of aerospace industries around the world. Particularly during the Cold War but even afterwards in times of increased international tensions, the major military powers used this venue to send messages regarding their abilities in the air and space domains. This year is likely to be no different.

It is noteworthy, therefore, that the U.S. Air Force, after some initial hesitancy, decided to allow two F-35A Joint Strike Fighters (JSF) to conduct a flight demonstration at the show. This is not the first time that U.S. F-35s have appeared in European air space. The Marine Corp F-35B, the short takeoff and vertical landing variant, participated in the 2016 Farnborough International Airshow. Earlier this year, eight F-35As conducted the first joint training deployment in the United Kingdom. These aircraft also made politically-important visits to both Estonia and Bulgaria.

Nevertheless, this planned F-35A flight demonstration is important on several levels. It is part of a concerted effort by the U.S. government to underscore its commitment to the security of Europe. It sends a message to friends and foes that the U.S. military leads the world in the development and deployment of fifth-generation aircraft. Visits to the United Kingdom and France also serve as reminders that the JSF is an international fighter and that seven NATO members invested their money in the program. In fact, these allies are planning to acquire several hundred F-35s. Finally, the flight demonstration will underscore the fact that virtually all of the JSFs teething problems are behind it.

The F-35 will not be going to Le Bourget alone. The Department of Defense will send many of its top-of-the-line aircraft and helicopters to Paris including the P-8A anti-submarine aircraft, the C-130J transport, the V-22 Osprey, AH-64 Apache and the CH-47 Chinook heavy-lift helicopter. These are among the best military aircraft in the world which is reflected in the continuing demand for them by friends and allies. In addition, the Textron/Airland team is sending its Scorpion, a light attack/intelligence, surveillance, and reconnaissance jet aircraft, to Le Bourget.

On the commercial side, Boeing is sending both its 737 MAX 9 and 787-10 Dreamliner flight test airplanes along with enhanced versions of its popular aircraft to the air show. Other U.S. companies that will provide display versions of their products include Gulfstream and Bell Helicopters.

Even the appearance at Le Bourget of non-U.S. commercial aircraft can say something important about the state of this countrys aerospace industry. The Canadian Company Bombardier, which debuts its C Series passenger jet at the 2015 air show, will be back looking for additional sales. Embraer, Brazils major aircraft producer, used the last air show to unveil its E-Jet E2 family of narrow-body, medium range commercial aircraft. It is reported that this year Airbus will publically fly for the first time its new A321neo, one of several variants in the family.

What these aircraft programs have in common is that they all are powered by Pratt & Whitneys advanced geared turbofan engine (GTF). The GTF also is on A320neos operated by numerous airlines and will power hundreds more that are on order. This engine provides a substantial improvement over those presently in service in terms of fuel use, noise level, emissions and operating costs.

The GTF has experienced some problems with respect to the reliability of specific components. Pratt & Whitney is taking steps to deal with these issues, which are not uncommon for new aviation products. Given the companys past successes in troubleshooting its products, including its development of a rapid solution to a fan blade rubbing problem with the F-35s engine, it is likely that GTFs problems will be solved.

Like the 51 air shows that have come before, the 2017 event will be a testament to the technological progress that continues to be made in the aerospace sector. It also will speak to the importance of the U.S. and its allies continuing to invest in aerospace capabilities that will ensure its military superiority over any potential adversaries.

Daniel Gour, Ph.D., is a Vice President of the Lexington Institute. He served in the Pentagon during the George H.W. Administration and has taught at Johns Hopkins and Georgetown Universities and the National War College. You can follow him on twitter @dgoure and you can follow the Lexington Institute @LexNextDC

Image: U.S. Air Force

Go here to see the original:

The Paris Air Show Will Showcase America's Aerospace Industrial Might - The National Interest Online (blog)

Russia’s Aerospace Force takes Briz-M booster to dump orbit – TASS

MOSCOW, June 8. /TASS/. The Titov Center of Russias Aerospace Force has taken the Briz booster from the designated orbit of the Echostar-21 satellite to a dump orbit, the Defense Ministry has told the media.

The US telecommunication satellite Echostar-21 was put in space on Thursday morning from the Baikonur space site in Kazakhstan with a Proton-M rocket, which blasted off at 06:45 Moscow time. The satellite entered the designated orbit nine hours and 13 minutes later.

"To remove the Briz-M booster from Echostar-21s orbit the engines were turned on twice. The booster was pushed into an orbit of about 2,000 kilometers at perigee and about 35,000 kilometers at apogee," the Defense Ministry said.

"Once the Briz-M booster was taken to a dump orbit the Aerospace Forces Space Control Center started analyzing and processing information concerning other space objects.

The booster and the satellite will be monitored by the chief center for space situation reconnaissance of Russias Aerospace Force.

In other media

Excerpt from:

Russia's Aerospace Force takes Briz-M booster to dump orbit - TASS

LMI Aerospace Shareholders Approve Merger Agreement for Acquisition by Sonaca Group – Advanced Manufacturing

Shareholders of LMI Aerospace Inc. (St. Louis), at a special meeting held June 8, approved the merger agreement for the Sonaca Groups acquisition of LMI. Under the terms of the agreement, LMI shareholders will be entitled to receive $14 per share in cash at the closing of the transaction.

LMI is supplier of structural assemblies, kits and components and provider of engineering services to the commercial, business and regional, and military aerospace markets. Sonaca Group is a global Belgian company active in the development, manufacturing and assembly of advanced structures for civil, military and space markets.

Shareholder approval is an essential milestone toward closing this transaction, said Dan Korte, LMI Aerospace CEO. With the strong support our shareholders gave today, we are one step closer to building a bright future together with the Sonaca Group.

We look forward to welcoming LMI Aerospace to the Sonaca Group, said Bernard Delvaux, Sonaca CEO. As complementary businesses with different core customers, we see opportunities to combine our strengths to better serve our customers and expand our market access globally.

Approximately 76.7 percent of outstanding shares voted, with more than 99.4 percent of votes cast in favor of the merger agreement and related transactions. LMI shareholders also approved, on an advisory (non-binding) basis, certain compensation that may be paid or become payable to LMIs named executive officers in connection with the transaction. LMI will file with the Securities and Exchange Commission Form 8-K with the final voting results on all agenda items. The transaction is subject to customary closing conditions, including required regulatory approvals. Closing is expected by the end of June 2017.

Excerpt from:

LMI Aerospace Shareholders Approve Merger Agreement for Acquisition by Sonaca Group - Advanced Manufacturing

‘Wonder Woman’a winner for best romantic chemistry in a superhero film – Sacramento Bee


Sacramento Bee
'Wonder Woman'a winner for best romantic chemistry in a superhero film
Sacramento Bee
Richard Donner's Superman spoiled us. When the Man of Steel first soared toward the heavens with Lois Lane on an exhilarating flyover date, the 1978 movie heightened our expectation for most superhero films to follow: Future costumed crimefighters ...
Entertaining 'Wonder Woman' is welcome addition to DC franchiseBuffalo News

all 873 news articles »

See more here:
'Wonder Woman'a winner for best romantic chemistry in a superhero film - Sacramento Bee

Atlanta student heads to Washington for chemistry competition – Atlanta Journal Constitution

School may be out for the summer, but one Atlanta student is still hitting the books for a chance to win a $12,000 scholarship in a national chemistry contest.

Matthew Propp from The Westminister Schools is one of 42 middle schoolers, selected by the Chemical Educational Foundaton, who will be heading to Washington, D.C., to compete in the 2017 You Be The Chemist Challenge. He was selected from a pool of 55,000 middle school students across 40 states, the nations capital and Puerto Rico.

These 42 students are evidence of what young people can achieve when they are inspired by chemistry. They are our future leaders and innovators. We look forward to hosting them in our nations capital and celebrating their accomplishments,CEF Executive Director Dwayne Sattler said.

The YBTC Challenge, an academic competition that encourages pupils to learn about the importance of chemistry, willhost its final showdown this month in DC. There,scholars will battle through rounds of chemistry questions until someone is crowned the Nation Challenge Champion.

The winner will receive a $12,000 educational scholarship and a TI-84 Plus calculator, 2nd place will receive a $6,000 scholarship, 3rd place a $3,000 scholarship and 4th place a $1,500 scholarship.

Check out the full list of finalistshere.

See the article here:
Atlanta student heads to Washington for chemistry competition - Atlanta Journal Constitution

Chargers optimistic budding chemistry will lead to more wins in L.A. … – ESPN (blog)

SAN DIEGO -- One of the goals for any new coach is to create a winning culture that unites players under one accord.

Los Angeles Chargers head coach Anthony Lynn believes hes accomplishing that task during offseason work at Chargers Park.

Under first-year strength coach John Lott, players were put through an arduous new conditioning program that focused on long-distance running, with the hope that the endurance training would lead to less injuries and better stamina at the end of games.

It was huge, Lynn said. If youre going to finish games in the fourth quarter, you have to be in shape. You and I both know it. It doesnt take talent to be in great shape. That can be a competitive advantage for us.

In addition, assistant coaches like defensive coordinator Gus Bradley and special-teams coordinator George Stewart have brought a new intensity and energy to the players they coach.

You can tell they really like one another, Lynn said. Its a competition, but you have veteran guys and the young guys. The young guys are standing out, working hard with veteran guys.

I like what were seeing from the team, chemistry-wise. I think thats why its so important were all here in the offseason and doing this together. Because when the season starts, you dont have time to build chemistry.

Unlike the other 31 NFL teams, the Chargers will be in the midst of relocating to Los Angeles once training camp starts at the end of July. After the teams mandatory minicamp from June 13-15 concludes, employees will pack up Chargers Park and begin the 100-mile move to Costa Mesa in Orange County.

The Chargers will hold training camp at Jack Hammett Sports Complex near Costa Mesa High School. Once training camp finishes at the end of August, the team plans to move into its new headquarters nearby.

The Chargers are also slated to play in the intimate 30,000-seat StubHub Center in Carson, California, for the next three seasons.

The transition to a new city could be a distraction for players. The Chargers only have to look at what happened last season to the Los Angeles Rams, who finished 4-12 and fired head coach Jeff Fisher near the end of the season.

Chargers players, however, believe the move a few hours north will not be an excuse for what happens on the field in 2017.

Im still a Charger, said cornerback Casey Hayward, who signed with the team as a free agent last offseason after spending his first four years in the NFL with the Green Bay Packers. Were still going to be in California, and in a great city in L.A. in the Orange County area, so you cant beat that. Were still going to be in sunny California, so I like it.

Lynn said the focus during minicamp next week will be fine-tuning what players have learned during offseason work.

We will continue our install, Lynn said. Well go back through it for the third time. Guys should own it, to be honest with you, next week. And they should play a little faster, a little more confident, but I still expect the same spirit, the same competition that you saw today.

Read more:
Chargers optimistic budding chemistry will lead to more wins in L.A. ... - ESPN (blog)

Packers QB Aaron Rodgers explains chemistry with Jordy Nelson – Packers Wire

Even during OTAs, Aaron Rodgers and Jordy Nelson are capable of producing the wow play for the Green Bay Packers.

During a team drill on Tuesday, Rodgers and Nelson delivered one of those special plays with Rodgers threading the needle between two defenders and Nelson contorting his body to get two feet inbounds along the back of the end zone for the score.

The chemistry between Rodgers and Nelson remains inextinguishable.

We know each other on the field really well, Rodgers said on Tuesday. He understands when the balls coming out, where he needs to be in certain spots. Weve done so many things in practice over the years. Hes always seeing the game through the quarterbacks eyes. He knows timing and spacing and second and third reactions better than anybody thats ever been here.

Even after Nelson missed the entire 2015 season with a knee injury, the connection between quarterback and receiver never suffered. Rodgers found Nelson for 97 completions and 1,257 yards in 2017, with 14 of the connections ending in touchdowns. No other quarterback and receiver combined for more last season.

How do two players so in sync get better during a June practice? Rodgers said the key is always working to build the chemistry.

Its just continuing to try and stay on the same page with him, and build, Rodgers said. Every season hes been healthy, weve had some pretty big years.

The numbers are undeniable. Over his last five healthy seasons, Nelson has produced 397 catches, 6,098 yards and 57 touchdowns with the majority of the production coming from the right arm of Rodgers. He also has four seasons with at least 1,200 yards and three with 12 or more touchdowns.

Rodgers and Nelson will enter their ninth season together in 2017. The chemistry between quarterback and receiver remains as strong as ever.

View original post here:
Packers QB Aaron Rodgers explains chemistry with Jordy Nelson - Packers Wire

American Chemistry Council updates PPE, hygiene guidelines for phosgene – Safety+Health magazine

Washington The American Chemistry Council recently released updated guidelines on preventive health measures and the use of personal protective equipment for workers exposed to phosgene, a chemical used in manufacturing that is a poisonous gas at room temperature.

To detect the presence of the phosgene, ACC recommends the use of monitoring badges, which change colors when exposed to the chemical. ACC added that remote optical sensing systems may be effective in identifying phosgene down a long path, rather than detecting its presence at a single point.

Badges should be placed in the breathing zone of a worker, and any badges potentially hindered by water or ultraviolet light should be placed underneath the front brim of a hard hat. Clips also may be used to keep badges attached to a collar, but wearing them underneath protective equipment or on the back of a hard hat could negate their effectiveness.

ACC suggests that organizations develop written instructions for the use of badges and establish a medical reporting system. The organization also recommends handling the gas in completely closed processing systems to decrease possible worker exposure.

If phosgene is released, ACC advises quickly evacuating the affected area and upon re-entry, using proper respiratory protection pressure demand full-face supplied air respirators in combination with an auxiliary self-contained breathing apparatus.

ACC also noted additional PPE to be used:

For decontamination purposes, ACC recommends that emergency response personnel seal any contaminated clothing/phosgene badges in airtight containers. Decontamination should be verified before respiratory protection is removed. Keep in mind, ACC states, that phosgene can remain trapped in low dips in pipes/equipment, process fluids or solids.

Read the original post:
American Chemistry Council updates PPE, hygiene guidelines for phosgene - Safety+Health magazine

The secret to great wine? Organic chemistry. – Chemical & Engineering News

[+]Enlarge

Waterhouse

Credit: Eleni Kardaras Photography

Vitals

Education: Ph.D., synthetic organic chemistry, University of California, Berkeley

Professional highlight: Honorary doctorate from the University of Bordeaux, a school with a wine program that dates back to 1880, the same year the viticulture and enology program started at the University of California

Favorite molecule: Acetaldehyde, which is a key wine oxidation product

Favorite way to enjoy a glass of wine: Barrel sampling with friends

Favorite city: Ljubljana, Slovenia. The food is wonderful; things are organized; there are many excellent local wines to taste and not too many tourists.

For Andrew L. Waterhouse, being tasked with wine selection when having drinks with family, friends, or inquisitive journalists is something of an occupational hazard. Its just part of the job, the professor of viticulture and enology at the University of California, Davis, says.

Its a good bet that Waterhouse will pick a winning wine. Hes widely respected for his expansive knowledge of wine chemistry and has educated a generation of winemakers during his 26 years teaching in UC Daviss world-renowned program.

But Waterhouse hasnt always been a wine connoisseur. With training in natural product synthesis, he started his career at a different school teaching organic chemistry primarily to premed students and researching conformational analysis of polysaccharides. One day, while paging through C&EN on a flight, Waterhouse saw a job posting for an assistant professor of viticulture and enology at UC Davis. He wanted to return to the West Coast, where he went to school, so he applied.

As soon as I heard I got the job, I started reading, he remembers. Professionally, I knew nothing. I was a wine lover, but I had no idea what was in wine, really, other than alcohol. Now he studies wines complex natural products, such as flavonoids. Winemakers call it chicken wire chemistry, he says, because the hexagons in the flavonoid structures resemble chicken wire to those untrained in chemistry.

Waterhouse says when he first started at UC Davis he tried to teach organic chemistry to budding winemakers the same way he taught it to premeds. It didnt work, he says. For example, when he taught his students about terpenesimportant flavor compounds in certain wines such as Rieslingshe discussed how the compounds undergo acid-catalyzed rearrangement during aging.

I was showing the students allylic cations forming, rearranging, and eliminating. And it was completely useless to them, he says. They have to understand something about terpene chemistry, but they dont have to understand mechanistic transformations from one terpene to another. This made Waterhouse completely rethink how he taught chemistry to these students. He needed to talk about chemistry that would be useful in wine making. Thats why they take classesthey want to understand whats happening so they can manage it better. Its a very applied use of chemistry.

And students of wine chemistry differ from premeds in another way, Waterhouse found. Whether the wine-making students are pursuing bachelors, masters, or doctoral degrees, all approach the subject with passion, Waterhouse says. When I was teaching organic chemistry to premeds, they had no interest in the subject. They just needed an A. It was a hurdle class for them and they didnt like it. Thats not the case with the students he teaches at UC Davis, he says. They really want to know the information, and they want to know why it is useful.

In 2016, after 25 years as a wine chemist, Waterhouse decided to create a resource for others who might be interested in teaching the subject or for chemists who are just interested in knowing more about the chemistry of wine. Along with Cornell Universitys Gavin L. Sacks and the University of Adelaides David W. Jeffery, he coauthored Understanding Wine Chemistry.

The book, he says, is different from other wine chemistry resources because it focuses on the organic chemistry of wine. Most of the chemists in the field are analytical chemists, and theyre very good at that, but when they write about it, they focus on analytical issues, such as comparing analytical results with taste and sensory results. While thats important, Waterhouse says, he and his coauthors wanted to create a book on the chemical reactions that take place in wine.

Just by understanding the chemistry you can intervene in very simple ways, Waterhouse notes. For example, sauvignon blanc wines from New Zealand are known for a guava- and passion-fruit-type aroma, but that fruity note would often be missing after storage. An organic chemist figured out that the aroma arises from an ester that can hydrolyze. Now, New Zealand winemakers keep the sauvignon blanc as cold as they can until its bottled and shipped, thus preserving that flavor. So understanding chemistry is very powerful, even in wine making, Waterhouse points out.

But, Waterhouse is quick to add, chemistry does not have all the answers. When I came to Davis, I thought all we have to do is figure out what are the key molecules that are present in great wine. Many people have this idea, and I was not any different. It turns out that there have been a lot of smart people thinking about this for a really long time, he says.

What Ive discovered is that its not really just the chemistry that makes wine interesting or valuable. Theres a lot more behind the story of wine than chemistry. I know that might be disappointing for some chemists, but the reality is that people love wine. And people love wine not just because of the way it tastes. They love wine for many reasons, he says. When youre a winemaker one of the key things you have to be able to do is convey a message about your producta story about yourself or the land or the history of the property. Those things are, in some way, more important to a wine drinker than wine that just tastes good.

Read this article:
The secret to great wine? Organic chemistry. - Chemical & Engineering News

Puma Biotechnology’s Neratinib Set To Target Extended Adjuvant Opportunity – Seeking Alpha

Puma Biotechnology (NYSE:PBYI) is inching closer to its transformation from a research and development (or R&D) biopharmaceutical company to a full-fledged commercial organization. This company which has in-licensed development and commercialization rights for oral and intravenous formulations of irreversible tyrosine kinase inhibitor or TKI, neratinib, and also another irreversible TKI, PB357, achieved the first major milestone for 2017 on May 24, 2017. On this day, FDA's Oncologic Drugs Advisory Committee or ODAC recommended approval for Nerlynx (neratinib) as extended adjuvant therapy for patients suffering with early stage, human epidermal growth factor receptor type 2 - positive or HER2-positive breast cancer after being previously treated with surgery and adjuvant treatment with Roche Holdings' (OTCQX:RHHBY) Herceptin (trastuzumab).

Besides this indication, Puma Biotechnology expects neratinib to demonstrate efficacy in other cancers such a non small cell lung cancer and tumors related to expression or over-mutation in HER2 such as HER2-positive cancer, HER-2 cancer that has metastasized to brain, HER2-positive neoadjuvant breast cancer.

Hence, there is high probability that Neratinib can prove to be a blockbuster drug for Puma Biotechnology. I believe this is a solid reason for considering the company as a favorable investment opportunity in 2017. In this article, I will explain the key drivers that make Puma Biotechnology a compelling investment opportunity in 2017.

Extended adjuvant setting is a larger underserved market segment

Currently, the target breast cancer market in extended adjuvant setting comprises around 36,000 patients in USA and 34,000 in EU. In 2015, Herceptin's sales in adjuvant indication were around $4.5 billion to $5.0 billion. All these patients form a target market for neratinib in the following year. Currently, letrozole is the only FDA approved therapy in extended adjuvant setting.

Puma Biotechnology expects to launch Neratinib as extended adjuvant breast cancer therapy in 2017

In July 2016, Puma Biotechnology filed new drug application or NDA with FDA, seeking approval for neratinib in extended adjuvant setting for early stage HER2-overexpressed/amplified breast cancer. The regulatory agency accepted the application in September 2016.

Further, the European Medicines Agency or EMA also validated Puma's application for neratinib in extended adjuvant setting in August 2016. On advice of EMA, in March 2017, the company revised its label to only include those early stage HER2+ breast cancer patients who had been previously treated for up to 1 year with adjuvant herceptin. Puma Biotechnology initiated a managed access program for neratinib in this indication in Q4 2016 and an expanded access program in Q1 2017.

While all these have been major milestones for the company in the past, the upcoming milestone will be FDA approval for orally administered neratinib in extended adjuvant setting, anticipated in 3Q 2017.

This approval is expected to be mainly based on results obtained from phase 3 trial, ExteNET, in which neratinib managed to hit its primary endpoints. In the intent-to-treat or ITT population, the 2-year disease free survival or DFS in neratinib arm was seen to be 93.9% while that in the placebo arm was 91.6%, which implies absolute improvement of 2.4%. In ITT population, there has been a 2.5% absolute improvement in 5-year DFS for neratinib arm as compared to placebo arm.

In case of patients confirmed with HER+ breast cancer, neratinib demonstrated 2-year DFS of 94.7%, while it was only 90.6% for the placebo arm. While this is an absolute improvement of 4.1%, the 5-year DFS with neratinib in HER+ patients is slightly higher at 4.4%.

Data from ExteNET trial has also shown 33% reduction in risk of disease recurrence for patients in neratinib arm as compared to those in placebo arm in ITT population. Further, for confirmed HER+ early stage breast cancer patients, the reduction in risk of disease recurrence for those on neratinib therapy in extended adjuvant setting is as high as 49%.

All these statistics are in line with those seen for the already approved extended adjuvant breast cancer drug, letrozole, as well as data obtained from development trials for hormone receptor positive or HR+ adjuvant breast cancer therapies, Pfizer's (NYSE:PFE) Aromasin and AstraZeneca's (NYSE:AZN) Arimidex. This implies that there are high chances for neratinib to secure FDA approval in extended adjuvant setting.

Neratinib has demonstrated higher benefit as adjuvant therapy in HR+ breast cancer patients

For HR+ breast cancer patients in ExteNET trial, the adjuvant therapy of neratinib demonstrated DFS rate of 95.4%, while the placebo arm showed DFS of 91.2%. This implied an absolute benefit of 4.2% after 2 years.

For 5-year period, the DFS with neratinib in HR+ patients was 91.7% while that in placebo arm was 86.9%, implying 4.8% absolute benefit.

Neratinib has demonstrated superior results in HR+ patients mainly on account of dual suppression of the crosstalk between estrogen receptor-positive or ER+ and HER+. Since ER+ breast cancer patients in the ExteNET trial were already on background endocrine therapy, it helped suppress the ER while neratinib suppressed both EGFR and HER2. This dual suppression has been seen only in neratinib and not in trials of other breast cancer drugs such Roche Holdings Herceptin and Novartis' (NYSE:NVS) Tykerb.

In case of HR- patients, however, ExteNET trial demonstrated improvement with neratinib between months 0 to 12 as compared to placebo. This was essentially when the patients were being administered the drug. However, the benefit in DFS in the neratinib arm over placebo arm seemed to become statistically insignificant over 5 year horizon.

Puma Biotechnology has also introduced loperamide prophylaxis therapy to prevent diarrhea resulting from neratinib.

Prior to Puma Biotechnology in-licensing Neratinib, it was being tested on 3,000 patients in various trials. It was seen that these patients suffered from grade 3 or grade 4 diarrhea in the first 28 days after initiating therapy. However, this could be treated with antidiarrheal drug, loperamide.

Puma Biotechnology is instead focusing on preventing this side-effect of neratinib using loperamide prophylaxis. Data from multiple studies has shown that the rate of grade 3 diarrhea reduced from the range of 30% to 53% in case of no loperamide prophylaxis to the range of 0% to 17% with loperamide prophylaxis. The total duration of diarrhea also dropped from 14 days to 2 days with loperamide prophylaxis.

Since ExteNET trial did not involve any anti-diarrheal prophylaxis therapy, Puma Biotechnology separately studied the impact of loperamide prophylaxis alone and in combination with other anti-inflammatory agents in extended adjuvant setting in early stage HER2+ breast cancer patients in another phase 2 trial, CONTROL. Data from this trial showed that while rate of grade 3 diarrhea in ExteNET trial was 39.8%, loperamide prophylaxis reduced the rate to 30.7%, loperamide and budesonide prophylaxis to 23.4%, and loperamide and colestipol to 11.5%.

Further, while the duration of diarrhea in ExteNET trial was 59 days, the various prophylaxis regimens in the CONTROL trial have brought the down to the range of 8 to 12 days. Episodes of diarrhea were also brought down from 8 in ExteNET trial to the range of 2 to 4 in CONTROL trial.

The CONTROL trial has also shown improvement in tolerability for the drug, which was being mainly affected due to diarrhea.

All this shows that the major side-effect of Neratinib, diarrhea, is easily manageable with effective prophylaxis therapy. Further, it is only seen that grade 3 diarrhea was witnessed by patients only in first cycle or first 28 days of neratinib therapy.

The company's cash reserves can sustain its operations through mid-2018

At the end of Q1 2017, Puma Biotechnology had $194 million worth cash reserves on its balance sheet. The company's cash burn rate in Q1 2017 was $36.0 million. This can be considered representative for all the quarters in 2017, as Puma has been highly involved in preparing for regulatory approval and commercial launch of neratinib. Based on these assumptions, the company can sustain its business operations upto the first half of 2018, without depending on external funding.

Further, with a solid oncology drug in the pipeline, Puma Biotechnology will also not find it difficult to raise capital from the public, either as equity or debt. Hence, the company seems to be at a comfortable position.

Investors should not ignore certain company-specific risks

Today, Puma Biotechnology is equivalent to neratinib. In absence of any commercial product or advanced stage research product, Puma Biotechnology is excessively dependent on the successful commercial launch of Neratinib. Since the product has not yet received FDA approval for even a single indication, this may prove to be too risky investment for investors with average risk appetite.

Further, the company also does not have proven marketing and distribution capabilities. In absence of a strong commercial partner, Puma Biotechnology may land up being commercially unsuccessful, despite securing FDA approval for neratinib.

Investors should consider these major risk factors while considering Puma Biotechnology as an opportunity in 2017.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.

Originally posted here:
Puma Biotechnology's Neratinib Set To Target Extended Adjuvant Opportunity - Seeking Alpha

ASU, Mexico partnership takes on biotechnology challenges – Arizona State University

June 6, 2017

Never in the history of human existence has the opportunity to genetically modify or protect life been as great and accessible to anyone interested in the topic as it is today.

Cures for human hereditary diseases. Designer babies. Glow-in-the-dark fish. Bioterrorism. Mosquitoes programmed to perish. The opportunities and risks are here now, but lagging are policies, ethical considerations and safety precautions needed to proceed prudently on an international scale.

Arizona State University experts will delve into the issues presented by biotechnology during the annual International Biosafety and Biosecurity Symposium (SIBB) held this year in Morelia, Mexico, and organized by the Asociacin Mexicana de Bioseguridad (AMEXBIO), June 710.

Were enhancing biosafety and biosecurity across international borders, said Irene Mendoza, associate biosafety officer with ASUs Office of Environmental Health and Safety, who will be one of the featured speakers at the symposium. Anything that affects Mexico, like the release of a pathogenic agent, can travel north and affect us.

Although infectious diseases willbe addressed at the symposium, the ASU delegation will lead a technical discussion on gene editing and gene drive technologies, said David Gillum, ASU Environmental Health and Safety associate director and institutional biosafety officer. In simplest terms, its about the ability to modify plants or mammals by manipulating their genome i.e., the chromosomes in each cell of an organism.

These technologies can drive a change in an entire species from just one modification, Gillum said. It can be propagated in all future generations.

David Gillum, ASU Environmental Health and Safety associate director and institutional biosafety officer, said that with the increased use of CRISPR Cas9 gene editing technology in Mexico comes great opportunities for ASU to form a more strategic partnership with AMEXBIO by conducting training sessions, lab site visits, joint research and other symposia.Photo by Charlie Leight/ASU Now

The gene drive of mosquitoes, for example, can be modified so the specific types that carry malaria and Zika will not reproduce and eventually die off. But once their genome is changed and released into the environment, there is no easy way to predict any unintended consequences.

Thats what is scary about it, Gillum said. Theres no easy undo button.

The leading gene editing method capable of making such changes is called CRISPR Cas9. This technological process takes advantage of the immune systems of bacteria to delete nucleic acids in living cells and replace them with the desired nucleic acid to change the genome.

When youre doing this genome editing, youre looking for very specific nucleic acids to change, Gillum said. Lets consider that you have sickle cell anemia and you have one gene that is wrong, and you just want to target that one gene. But the genome is huge; there are billions of base pairs. So how do you make sure that you target the one that youre looking for and not similar sequences somewhere else in your body?

Unlike past costly and complex genome editing technologies, CRISPR Cas9 is simpler, relatively inexpensive and thus more accessible to people who may not be working in a modern laboratory with established biosafety policies and procedures.

There are a lot of citizen labs all over the place where science enthusiasts are getting together in their garages and experimenting, Mendoza said. The risk is that although they may just be trying to do something fun, what they create may have unintended consequences.

Irene Mendoza, associate biosafety officer with ASUs Office of Environmental Health and Safety, will be one of the featured speakers during the annual International Biosafety and Biosecurity Symposium held this week in Morelia, Mexico, and organized by the Asociacin Mexicana de Bioseguridad.

The use of CRISPR Cas9 has increased in Mexico in the past few years, Gillum said. Experts there recognize the challenge, and that drives such events as the SIBB, which includes participation from other Latin American countries.

What we want to achieve in SIBB is to continue the academic efforts of diffusing specific knowledge on biosafety and biosecurity, as well as raise awareness among those involved in manipulating biological agents, said Luis Alberto Ochoa Carrera, AMEXBIO president and founder. The importance of the work of AMEXBIO is based on the need to create a biosafety culture and appropriate communication within institutions to mitigate risks associated with experimenting with biological agents.

ASU contacts AMEXBIO remotely throughout the year, but opportunities exist to engage in person and at a higher level by way of training sessions, site visits, joint research and other symposia to address the wide array of biosafety and biosecurity aspects.

There is a huge opportunity here for ASU and AMEXBIO in Mexico to partner on these projects, Gillum said. Theyre very interested in biodefense. Were looking into philanthropy to help with funding that will allow us to form a more strategic partnership.

With funding, ASU biosafety experts like Gillum and his team can work with AMEXBIO to visit labs in Mexico to observe operations and offer suggestions on improving safety and security.

The interesting aspect of biosafety is that in general its based on best management practices, Gillum said. Except for very highly pathogenic agents and toxins, everything else is done with a best management practices point of view. Theres not always a black-and-white way to do certain things.

Forming strategic links between biosafety and biosecurity experts across the border enables mutual collaboration and training in the region, Ochoa Carrera said.

AMEXBIO recognizes ASUs efforts and transcendence in Mexico and within the international biosafety community, Ochoa Carrera said. The ASU and AMEXBIO alliance enables the dissemination of knowledge in this field, and its also an area of opportunity between Mexico and the United States.

Top photo: DNA sequence, courtesy freeimages.com.

See more here:
ASU, Mexico partnership takes on biotechnology challenges - Arizona State University

Puma Biotechnology announces positive trial results – Seeking Alpha

Puma Biotechnology (NYSE:PBYI) presents at ASCO thepositive results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 for the treatment of HER2-positive metastatic breast cancer that has metastasized to the brain.

The multicenter Phase II clinical trial enrolled patients with HER2-positive metastatic breast cancer who have brain metastases. The trial is being performed by the TBCRC and enrolled three cohorts of patients.

We are very pleased with the activity seen in this trial with the combination of neratinib plus capecitabine, sys Puma CEOAlan Auerbach.

As a small molecule that can cross the blood brain barrier, neratinib potentially offers patients with HER2-positive metastatic breast cancer that has metastasized to the CNS a novel HER2 targeted treatment option. We look forward to working with TBCRC on future trials of neratinib in patients with HER2-positive disease metastatic to the CNS," he adds.

Source: Press Release

#ASCO

Read more here:
Puma Biotechnology announces positive trial results - Seeking Alpha

WSJ’s Grant: In biotech, no news is bad news – Seeking Alpha

The American Society of Clinical Oncology annual meeting passed without much of a stir, writes Charley Grant in the WSJ. Naturally, there were exceptions with individual companies, but the biotech sector as a whole barely budged throughout the major conference.

So what? The S&P Biotechnology Select Industry Index isup 19%in 2017, and there are treatment categories outside of oncology. But, says Grant, the majority of stocks in that index aren't profitable, and are thus dependent on things like ASCO to rev up sentiment. In the bull market of 2013-15, ASCO was enough to send the sector sharply higher.

With that catalyst not working this year, all biotech may have to look forward to are blockbuster drug launches, and there's not much going on there - just three drugs are set to come to market this year that are expected to top $2B in annual sales by 2022.

ETFs: IBB, XBI, LABU, BBH, FBT, HQL, PBE, LABD, BBC, BBP, UBIO, ZBIO, LABS

Read this article:
WSJ's Grant: In biotech, no news is bad news - Seeking Alpha

Fluence Bioengineering Improves Year-Round Quality and Consistency of Crop Production at Hllns Handelstrdgrd – Benzinga

Swedish producer of leafy greens, herbs, and ornamental flowers grows faster and better during winter than summer since switching from HPS to Fluence VYPRx PLUS LED solutions

Austin, TX (PRWEB) June 08, 2017

Fluence Bioengineering today announced Hllns Handelstrdgrd, one of Sweden's largest producers of organic leafy greens, herbs, and ornamental flowers, has seen a dramatic improvement in crop production since upgrading its supplemental greenhouse lighting from high pressure sodium (HPS) to Fluence LED-based solutions. The upgrade to Fluence LED solutions has increased bench turns, crop yield and quality, and energy efficiency coupled with a decrease in lead time and shrink.

To help Hllns Handelstrdgrd achieve their goals of increasing year-round, consistent crop production, Fluence developed lighting solutions specific to their unique growing conditions just south of the Arctic Circle in Northern Sweden. To learn more, and to get a behind-the-scenes look into Hllns Handelstrdgrd's operation, visit http://fluence.science/hallnas

"We are seeing reduced lead times and higher yields under the Fluence LED systems, with finished product quality that exceeds everything we have seen before," said Bjrn Isacsson, owner at Hllns Handelstrdgrd. "Not only have the products from Fluence surpassed our expectations, but the team has proven invaluable with support and services to help our business grow."

"All we can see are these great results: better quality and more compact plants," said Philip Stawarz, Head Grower at Hllns Handelstrdgrd. "Growing with HPS was like it was, lamps on or off. Now with Fluence, life is much more interesting as I can manipulate plants how I want."

With the addition of VYPRx PLUS lighting solutions, Hllns is now able to grow higher quality plants faster during winter (when there is little sunlight), than during the summer due to the improved light intensity and spectrum, and ideal growing environment Fluence lighting solutions create. The company has deployed VYPRx PLUS with PhysioSpec Greenhouse, a broad spectrum for full-cycle plant growth and development, along with VYPRx PLUS with AnthoSpec, a custom narrow-band spectrum which increases anthocyanin accumulation in lettuce. The deployment of AnthoSpec resulted in a deep red color and higher antioxidant properties which were previously unattainable under HPS or sunlight.

"It is a pleasure working with the team at Hllns Handelstrdgrd as we collaborate to develop solutions which have proven to successfully help them achieve their cultivation and financial goals," said Nick Klase, Co-Founder and CEO at Fluence Bioengineering. "Every environment and every customer's needs are uniquethat's why we focus on building deep relationships with our customers to achieve results which are unattainable by any other means."

In addition to Hllns Handelstrdgrd, VYPRx PLUS LED systems have been deployed at hundreds of commercial crop production facilities and research institutions worldwide. Fluence lighting solutions have been independently verified to be the most energy efficient, powerful and efficacious, resulting in high-quality, high-yield crop production facilities. Learn more at https://fluence.science/vypr

About Fluence Bioengineering Fluence Bioengineering is a photobiology design company exploring physiological plant development under various levels of photosynthetically active radiation and custom spectra. The company partners with leading research institutions to engineer the most powerful and efficient horticulture lighting solutions for both science and commercial applications. All Fluence systems are designed and built in Austin, TX, USA. https://fluence.science

###

For the original version on PRWeb visit: http://www.prweb.com/releases/2017/06/prweb14401620.htm

Continued here:
Fluence Bioengineering Improves Year-Round Quality and Consistency of Crop Production at Hllns Handelstrdgrd - Benzinga